Navigation

Summary of Results

Health Topic:   Musculoskeletal
Guidance:   Rheumatoid arthritis - adalimumab, etanercept and infliximab
Description:   The summary of the published technology appraisal on Rheumatoid arthritis - adalimumab, etanercept and infliximab. It links to the published guidance and key documents.

NICE implementation uptake reports

Implementation uptake report Assessment Published Date Coverage

External literature

External literature Assessment Coverage

National Audit Office (2009) Services for people with rheumatoid arthritis National Audit Office

Description: A report examining the efficiency and effectiveness of services for people with RA. The study found 86% of acute trusts are able to prescribe biologics to all patients in accordance with NICE guidance. In 2007-08, 11,900 patients qualified for biologics according to the criteria in the TA, and on average 97% received the drugs for which they qualified.

Practice appears to be in line with guidance National

All Wales Medicines Strategy Group (2011) Monitoring of AWMSG recommendations

Description: This paper covers medicines that have been recommended by the All Wales Medicines Strategy Group (AWMSG) for use in NHS Wales. Five of these medicines, Adalimumab, Teriparatide, Topotecan Hydrochloride, Bortezomib and Docetaxel are also covered by a NICE Technology Appraisal. The report includes hospital and homecare usage data for three of these drugs, Adalimumab, Teriparatide, Topotecan Hydrochloride.

Not graded Regional

Kobelt, G et al (2009) Access to innovative treatments in Rheumatoid Arthritis In Europe

Description: This report compares usage of NICE positively appraised Rheumatoid Arthritis drugs in England (abatacept, rituximab, adalimumab, infliximab, etanercept), with other countries drug usage. Cost and volume data from IMS data and average annual dose per patient and drug were used to estimate the patient numbers treated by country. It should be noted that countries other than the UK would not be expected to adhere to NICE guidance making comparisons between countries not possible.

Not graded National

Richards, M (2010) Extent and causes of international variation in drug usage: A report for the Secretary of State for Health by Professor Sir Mike Richards CBE

Description: This report looks at medicines usage between countries, using IMS Health data. The WHO defined daily dose or the maximum or prescribed daily dose was used to measure usage. Results rank the UK relative to other countries usage and present calculations showing how close or otherwise the UK is to the average use across groups of other countries. It should be noted that countries other than the UK would not be expected to adhere to NICE guidance making comparisons between countries not possible.

Not graded National

This page was last updated: 03 March 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.